Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

NCT01040780 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

399

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Icotinib
DRUG: Gefitinib

Sponsor

Betta Pharmaceuticals Co., Ltd.